Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | PDE6D | O43924 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PDE9A | O76083 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaprinast SCHEMBL30276335 | 1.00 | PDE5A (0.56) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| SCHEMBL4452818 | 0.82 | PDE5A (0.68) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| Zaprinast SCHEMBL6374345 | 0.81 | PDE5A (0.70) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| SCHEMBL7076702 | 0.79 | PDE5A (0.62) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| SCHEMBL14174617 | 0.79 | PDE5A (0.46) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| Zaprinast SCHEMBL50328 | 0.79 | PDE5A (0.65) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| SCHEMBL29230010 | 0.76 | PDE5A (0.56) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| SCHEMBL7722659 | 0.75 | PDE5A (0.67) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| SCHEMBL7406940 | 0.74 | PDE5A (0.73) | PDE5AKDM4EALDH1A1KMT2AGLA | |
| Zaprinast SCHEMBL6617495 | 0.73 | PDE5A (0.58) | PDE5AKDM4EALDH1A1KMT2AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5994 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250319110-A1 | SURFACE CALR CHEMICAL INDUCERS | ZON LEONARD (US) | 2025-10-16 | — | — | US | claimed |
| US-20250195531-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-06-19 | — | — | US | claimed |
| EP-4540374-A1 | SURFACE CALR CHEMICAL INDUCERS | The Children's Medical Center Corporation (US) | 2025-04-23 | — | — | EP | claimed |
| US-12268660-B2 | Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension | AARDVARK THERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-12251582-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2025-03-18 | — | — | US | claimed |
| WO-2025023901-A1 | THE PHARMACEUTICAL COMBINATION COMPRISING PHOSPHODIESTERASE TYPE-5 INHIBITOR AND L-ARGININE | MONTERO GIDA SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-30 | — | — | WO | claimed |
| WO-2025023902-A1 | THE PHARMACEUTICAL COMBINATION COMPRISING PHOSPHODIESTERASE TYPE-5 INHIBITOR, L-ARGININE AND PANAX GINSENG | MONTERO GIDA SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-30 | — | — | WO | claimed |
| US-20240238259-A1 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION | AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER | 2024-07-18 | — | — | US | claimed |
| EP-4356142-A1 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | Endothelium Scanning Nanotechnology Limited (AU) | 2024-04-24 | — | — | EP | claimed |
| EP-0777482-A1 | COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | claimed |
| EP-0776207-A1 | USE OF ZAPRINAST FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ACUTE RENAL FAILURE | WASHINGTON UNIVERSITY (US) | 1997-06-04 | — | — | EP | claimed |
| EP-0754069-A1 | METHODS FOR TREATING PULMONARY VASOCONSTRICTION AND ASTHMA | THE GENERAL HOSPITAL CORPORATION (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1996025184-A1 | TREATMENT OF VASCULAR THROMBOSIS AND RESTENOSIS WITH INHALED NITRIC OXIDE | THE GENERAL HOSPITAL CORPORATION (US) | 1996-08-22 | — | — | WO | claimed |
| US-5521191-A | ADMINISTERING ZAPRINAST | WASHINGTON UNIVERSITY (US) | 1996-05-28 | — | — | US | claimed |
| WO-1996011688-A1 | USE OF ZAPRINAST FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING VASCULAR RESTENOSIS | WASHINGTON UNIVERSITY (US) | 1996-04-25 | — | — | WO | claimed |
| WO-1996005835-A1 | USE OF ZAPRINAST FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ACUTE RENAL FAILURE | WASHINGTON UNIVERSITY (US) | 1996-02-29 | — | — | WO | claimed |
| WO-1996005838-A2 | COMBINED PREPARATION FOR THE THERAPY OF IMMUNE DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-02-29 | — | — | WO | claimed |
| US-5486519-A | ADMINISTERING ZAPRINAST | WASHINGTON UNIVERSITY | 1996-01-23 | — | — | US | claimed |
| WO-1995026768-A1 | METHODS FOR TREATING PULMONARY VASOCONSTRICTION AND ASTHMA | THE GENERAL HOSPITAL CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |